Printer Friendly

PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS SIGN FINAL AGREEMENT TO FORM PERISIS

 BOSTON, March 16 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIP) and PerSeptive Biosystems, Inc. (NASDAQ: PBIO) jointly announced today at Cowen & Company's Annual Health Care Conference that they signed final agreements relating to the formation of PerIsis. This strategic alliance will pursue the development of novel tools for the manufacture of oligonucleotide therapeutics. The collaboration will focus on the application of PerSeptive's proprietary Perfusion Chromatography(R) technology for the purification, analysis and synthesis of oligonucleotides.
 Under the terms of the arrangement, PerSeptive will have the option to commercialize novel purification, analysis and synthesis products developed by this venture. The companies have also agreed to a bilateral royalty arrangement on each company's sales of certain oligonucleotide-related products.
 Isis and PerSeptive will focus on developing novel purification protocols to reduce the time required for purification, improve levels of purity, increase yield of oligonucleotide product and lower production costs. Isis and PerSeptive will also conduct research on the use of PerSeptive's POROS(R) media as supports for the large-scale synthesis of oligonucleotides.
 Isis Pharmaceuticals, based in northern San Diego County, is engaged in the discovery and development of novel human therapeutic products based on proprietary oligonucleotide analogs. Isis has a broad oligonucleotide research program, has multiple compounds in preclinical development and its first oligonucleotide-based drug, ISIS 2105, is in Phase II clinical trials.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography(R), ImmunoDetection(tm) and Rational Surface Design(tm).
 -0- 3/16/93
 /CONTACT: Jacqueline G. Siegel, Ph.D., Christopher K. Mirabelli, 619-931-9200 of Isis Pharmaceuticals, Inc., or Robert A. Fein of PerSeptive Biosystems, Inc., 617-621-1787/
 (ISIP PBIO)


CO: PerSeptive Biosystems; Isis Pharmaceuticals ST: Massachusetts, California IN: MTC SU:

TM -- NE002 -- 6391 03/16/93 08:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1993
Words:335
Previous Article:NUTRITIONISTS AND UNIVERSITY RESEARCHERS LIST NATURE'S MOST POTENT 'POWER PACKS'
Next Article:CANCER PUBLISHES RESULTS OF TREATMENT OF C-TTP/HUS WITH IMRE CORPORATION'S PROSORBA COLUMN
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS ANNOUNCES THE EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 375,000 SHARES, COMPLETING ITS INITIAL PUBLIC OFFERING
PERSEPTIVE BIOSYSTEMS SUBMITS DRUG MASTER FILE WITH FDA COVERING POROS CHROMATOGRAPHY MEDIA
PERSEPTIVE BIOSYSTEMS NAMES JOHN CURLING VICE PRESIDENT, INTERNATIONAL BUSINESS DEVELOPMENT
PERSEPTIVE BIOSYSTEMS NAMES HUBERT M. QUINN VICE PRESIDENT, CHEMICAL PRODUCTION
PERSEPTIVE BIOSYSTEMS AND ISIS PHARMACEUTICALS ANNOUNCE THE FORMATION OF PERISIS: A STRATEGIC ALLIANCE FOR OLIGONUCLEOTIDE MANUFACT. TECHNOLOGIES
PERSEPTIVE BIOSYSTEMS NAMES ALAIN MASSOT SENIOR VICE PRESIDENT, INTERNATIONAL
PERSEPTIVE BIOSYSTEMS ANNOUNCES ALLOWANCE OF PATENT CLAIMS ON PERFUSIVE CHROMATOGRAPHY PARTICLES
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THIRD QUARTER RESULTS
PERSEPTIVE BIOSYSTEMS ANNOUNCES FILING OF REGISTRATION STATEMENT RELATING TO PERSEPTIVE TECHNOLOGIES II CORP.
PERSEPTIVE BIOSYSTEMS COMMENCES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters